-
HSP90 Regulates RNA Foci in Myotonic Dystrophy Type 1
2026-08-31
Johnson et al. used an unbiased RNA-FISH small-molecule screen to identify HSP90 as a regulator of pathogenic DMPK mRNA and CUG-repeat RNA foci in Myotonic Dystrophy type 1. The study further connects HSP90 activity to p-STAT3 in undifferentiated myoblasts while revealing a differentiation-dependent reversal of the response, providing a framework for studying RNA-foci homeostasis rather than only foci reduction.
-
Gut-Brain Cholinergic Signaling in B. fragilis
2026-08-31
Jia et al. identify a vagal gut-brain cholinergic circuit through which Bacteroides fragilis suppresses seizures, linking colonic ChAT-positive cells with antiseizure activity in mice. The combination of microbiome analysis, neural recordings, circuit manipulation, and a pediatric clinical trial provides a mechanistic framework for microbiota-targeted epilepsy research.
-
GCRV104 Entry Through Clathrin-Mediated Endocytosis
2026-08-30
Wang et al. combined pharmacological inhibition, transmission electron microscopy, and RT-qPCR to show that genotype III grass carp reovirus GCRV104 enters CIK cells through a dynamin-dependent, clathrin-mediated pathway requiring endosomal acidification. The study distinguishes inhibitors that suppress infection from those without measurable activity, providing a useful framework for investigating aquaculture virus entry while highlighting the limits of drug-based pathway assignments.
-
Solanesol (B8776): Practical Workflow Guide
2026-08-29
Solanesol is a hydrophobic polyisoprenoid alcohol for controlled biochemical, membrane-related, and enzyme-focused research workflows. This guide explains DMSO-based preparation, solvent-matched controls, storage, and assay limitations; it should not be used in water- or ethanol-based formulations or for diagnostic, clinical, or medical applications.
-
Tetrazolium (chloride) for Viability Assays
2026-08-28
Tetrazolium (chloride), also called Tetrazolium Red or TTC, converts mitochondrial dehydrogenase activity into a visible red formazan signal. Its flexibility supports both high-throughput cell viability assays and spatial tissue ischemic necrosis detection in stroke and cardiac injury research.
-
Formononetin Protects Against Oxaliplatin Neurotoxicity
2026-08-28
The reference study identifies formononetin as a selective neuroprotective candidate for oxaliplatin-induced peripheral neurotoxicity, acting through Nrf2/HO-1 antioxidant signaling and reduced neuronal apoptosis. Its key translational finding is that neuronal protection was achieved without weakening oxaliplatin or paclitaxel activity in cancer-cell models, although protection against paclitaxel-related neurite damage was limited.
-
Sorafenib: From Kinase Potency to Tumor Phenotype
2026-08-27
Sorafenib and BAY-43-9006 are more than multikinase inhibitors: they enable experiments that separate tumor-cell signaling from endothelial angiogenesis. This guide connects potency data, assay architecture, hepatocellular carcinoma models, and recent VEGFR-2 inhibitor findings to improve mechanistic interpretation.
-
Sodium Phosphate Dibasic for Reliable Bioassays
2026-08-27
Sodium phosphate dibasic (Na2HPO4) is more than a routine buffer ingredient: its chemistry can determine whether biological assay endpoints reflect the test compound or the matrix. This guide connects phosphate-buffer design with aquatic toxicology findings to improve pH control, vehicle matching, and reproducibility.
-
SU 5402 Workflows for RTK Signaling Research
2026-08-26
SU 5402 enables time-resolved interrogation of VEGFR2, FGFR1, PDGFRβ, and downstream ERK1/2–STAT3 signaling across cancer and exploratory human-neuron assays. This practical guide links dose planning, phosphoprotein measurements, cell fate readouts, and troubleshooting to help distinguish pathway inhibition from nonspecific toxicity.
-
7ACC2: Monocarboxylate Transporter 1 Inhibitor
2026-08-26
7ACC2 combines potent MCT1 blockade with interference in mitochondrial pyruvate transport, enabling more informative studies of lactate flux than a single-pathway perturbation. This workflow-focused guide shows how to measure transport, connect tumor metabolism with macrophage immunobiology, and troubleshoot interpretation without overstating translational maturity.
-
ABT-263 (Navitoclax) in Apoptosis Research
2026-08-25
Use ABT-263 (Navitoclax) as a mechanistic benchmark for Bcl-2-family inhibition, dose-response studies, and caspase-dependent apoptosis research. Its value extends into senescence assays, where matched senescent and proliferating controls can reveal whether cell death is selective rather than merely cytotoxic.
-
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-08-25
Grafton and colleagues developed a scalable assay that combines human induced pluripotent stem cell-derived cardiomyocytes, high-content imaging, and deep learning to identify morphological patterns associated with drug-induced cardiotoxicity. The approach converted complex cellular phenotypes into a single screening score, offering an early de-risking strategy while still requiring electrophysiological and mechanistic validation.
-
FGFR3 Inhibition in SLC26A2 Chondrodysplasia
2026-08-24
The reference study combines genetic models, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia. Its findings support NVP-BGJ398 as a research tool for testing FGFR3 pathway inhibition, while also highlighting the limits of translating mouse growth-plate results directly to human treatment.
-
Rifampin as a Translational Tool for Bacterial Transcription
2026-08-24
Rifampin is more than a bactericidal antibiotic: it is a precise perturbation tool for connecting bacterial RNA polymerase activity with resistance, transcriptional regulation, and synthetic biology outcomes. This article outlines how translational researchers can use its mechanism, handling profile, and experimental limitations to build stronger evidence packages.
-
IDH1-R132H Autopalmitoylation in Cancer
2026-08-23
The reference study identifies C269 autopalmitoylation as a mutation-specific regulator of IDH1-R132H, linking fatty-acid availability to 2-HG-producing activity, dimerization, and oncogenic phenotypes. Its combination of chemical-probe profiling, cysteine mutagenesis, biochemical assays, and cellular validation provides a mechanistic framework for studying a druggable hydrophobic pocket in IDH1-mutant cancers.